SINGLE-ARM, PHASE 1B, OPEN-LABEL STUDY ASSESSING THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF REPEAT-DOSE SUBCUTANEOUS ANX009 PLUS STANDARD OF CARE IN ADULT PATIENTS WITH LUPUS NEPHRITIS

Chronic Kidney Disease, Hypertension, Diabetes and CVD

Chronic Kidney Disease Diagnosis, Classification and Progression

 

 

 

 

Chen, H.C.(1);Lichauco, J.J.(2);Gomez, H.M.(3);Tee, M.(4);Arroyo, C.(5);Lan, J.L.(6);Fang, Y.F.(7);Chang, Q.(8);Osterloh, J.(9)*;Miles, A.(10);Chang, E.(11);Mongan, A.(11);Kroon, H.A.(12);

(1)Tri-Service General Hospital, Division Of Rheumatology/Immunology/Allergy, Taipei City, Taiwan;(2)St. Luke’S Medical Center, Department Of Medicine, Quezon City, Philippines;(3)Angeles University Foundation Medical Center, Department Of Internal Medicine, Pampanga, Philippines;(4)Medical Center Manila, Department Of Internal Medicine, Manila, Philippines;(5)Iloilo Doctors Hospital, Department Of Internal Medicine, Iloilo City, Philippines;(6)China Medical University Hospital, Division Of Immunology And Rheumatology, Taichung, Taiwan;(7)Chang Gung Memorial Hospital, Division Of Rheumatology- Allergy And Immunology, Linkou, Taiwan;(8)Annexon Biosciences, Portfolio Strategy And Management, Brisbane, United States;(9)Annexon Biosciences, Portfolio Strategy & Operations, Brisbane, United States;(10)Annexon Biosciences, Global Clinical Operations, Brisbane, United States;(11)Annexon Biosciences, Clinical Biomarkers, Brisbane, United States;(12)Annexon Biosciences, Translational Medicine, Brisbane, United States;

https://storage.unitedwebnetwork.com/files/1041/e91781fc2faad71955f7cf994c354bf2.pdf